Individuals with opioid use disorder who were prescribed a lower buprenorphine dose were 20% more likely to discontinue treatment than those on a higher dose, according to a study of patients prescribed buprenorphine in Rhode Island from 2016 to 2020, as fentanyl became widely available.
Chartis Acquires HealthScape Advisors to Strengthen Payer Expertise
What You Should Know: – Chartis, a healthcare advisory firm, announced today the acquisition of HealthScape Advisors, a prominent healthcare payer consulting firm from Convey